Percy H. Carter

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 345 citations · Full text

Total Synthesis of Bryostatin 2

David A. Evans, Percy H. Carter, Erick M. Carreira et al. · Journal of the American Chemical Society · 1999 · 254 citations

Synthesis Plan, Medicinal Chemistry, Bioorganic Chemistry +12

Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Scott H. Watterson, George V. De Lucca, Qing Shi et al. · Journal of Medicinal Chemistry · 2016 · 142 citations · Full text

Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α

Percy H. Carter, Peggy Scherle, Jodi A. Muckelbauer et al. · Proceedings of the National Academy of Sciences · 2001 · 136 citations · Full text

Crystal Structure, Immunology, Cell Death +20

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand et al. · Journal of Medicinal Chemistry · 2019 · 104 citations · Full text

Tyrosine Kinase, Immunology, Quantitative Pharmacology +20